Drug intelligence / Profile preview

177Lu-NY108

Development stage: Unknown
Lead developer: Affiliated Hospital of Jiangnan University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-NY108 is an investigational radiopharmaceutical consisting of the anti-prostate-specific membrane antigen (PSMA) monoclonal antibody NY108 conjugated to the beta-emitting radioisotope lutetium-177 (177Lu). Developed by the Affiliated Hospital of Jiangnan University, it is designed for targeted radionuclide therapy and SPECT imaging of metastatic castration-resistant prostate cancer (mCRPC). The NY108 antibody component specifically targets PSMA, a protein highly expressed on the surface of prostate cancer cells, allowing for the localized delivery of ionizing radiation to tumor sites while minimizing damage to healthy tissues. It is currently being evaluated in early-phase clinical trials to assess safety, biodistribution, and imaging potential.

Other names: 177Lu-labeled NY108Lutetium (177Lu) NY108

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-NY108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-NY108.

Explore the full profile